WO1998018907A1 - Verfahren zur herstellung von tumoriziden t-lymphozyten - Google Patents
Verfahren zur herstellung von tumoriziden t-lymphozyten Download PDFInfo
- Publication number
- WO1998018907A1 WO1998018907A1 PCT/EP1997/005957 EP9705957W WO9818907A1 WO 1998018907 A1 WO1998018907 A1 WO 1998018907A1 EP 9705957 W EP9705957 W EP 9705957W WO 9818907 A1 WO9818907 A1 WO 9818907A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lymphocytes
- cells
- tumoricidal
- tumor
- antibody
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000008569 process Effects 0.000 title claims abstract description 9
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 47
- 230000002476 tumorcidal effect Effects 0.000 claims description 36
- AJMOLNFDYWTVQW-QWRGUYRKSA-N L-leucyl-l-leucine methyl ester Chemical compound COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C AJMOLNFDYWTVQW-QWRGUYRKSA-N 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 238000011534 incubation Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 23
- 210000004881 tumor cell Anatomy 0.000 description 21
- 244000005700 microbiome Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 8
- 102100039564 Leukosialin Human genes 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108010062054 leucyl-leucine-methyl ester Proteins 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010032838 Sialoglycoproteins Proteins 0.000 description 2
- 102000007365 Sialoglycoproteins Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000995200 Homo sapiens Neurabin-2 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 102000050471 human SPN Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Definitions
- the invention relates to a process for the activation, production and multiplication of tumorous T lymphocytes and a composition which is suitable as a medium for the production, activation and multiplication of tumorous T lymphocytes.
- the cellular immune defense plays an important role in the elimination of pathologically altered body cells such as virus-infected cells or tumor cells.
- cytotoxic T-lymphocytes recognize the changed body's own cells based on surface antigens.
- surface antigens are usually protein fragments that are formed by the cells and are present on the cell surface bound to surface receptors of the so-called major histocompatibility complex (MHC) (Zinkernagel et al., Nature 248 (1974), 701-702 and Babbit et al., 1985, Nature 317: 359-361).
- MHC major histocompatibility complex
- LAK cells lymphokine-activated killer cells
- the lymphocytes to be activated were also cultivated in the presence of autologous tumor cells (mixed lymphocyte tumor cultures, G. Fossati et al., International Journal of Cancer 42 (1988), 239-245; G. Degiovanni et al., Eur. J. Immunol. 18 (1988), 671-676; Wölfel et al., J. Exp. Med. 170 (1989), 797-810; Darrow et al., J. Immunol. 142 ( 1989), 3329-3335 and Notter et al., Int. J. Cancer 45 (1990), 834-841).
- autologous tumor cells mixed lymphocyte tumor cultures, G. Fossati et al., International Journal of Cancer 42 (1988), 239-245; G. Degiovanni et al., Eur. J. Immunol. 18 (1988), 671-676; Wölfel et al., J. Exp. Med. 170 (1989), 797-810; Darrow
- TLL tumor infiltrating lymphocytes
- WO 94/23014 describes tumoricidal T lymphocytes and a process for their preparation. Thereafter, tumor tidal lymphocytes are produced by co-cultivating lymphocytes with a mammalian cell line of certain properties.
- the object of the invention was to provide an improved and simplified method for the specific production of specifically tumoricidal T-lymphocytes, the Stimulation and proliferation of other T lymphocytes, and in particular of NK cells, is avoided
- tumoricidal T-lymphocytes which cells of a chronic myelogenic leukemia cell line (K-562, ATCC CCL 243) do not destroy cytotoxically, but only inhibit their growth for a limited period of time, by cultivating lymphocytes which are lysosomotrophic be pretreated with anti-CD43 antibodies and isolation of the tumoricidal T lymphocytes.
- lymphocytes white blood cells
- sucker cell line a sucker cell line
- Tumor lymphocytes in the sense of the invention, are T cells, as described in WO94 / 23014 and which recognize tumor cells in an antigen-unspecific manner and are killed by apoptosis induction and / or cytolysis. T tumor lymphocytes are characterized in that
- no interleukin-2 is detectable in the culture supernatant of these tumorous T lymphocytes during the proliferation of these cells in the presence of the HB 654 or HB 617 cell line at a detection limit of 0.5 IU / ml
- Tumor-killer T cells are not natural killer (NK) lymphocytes. Compared to tumor-infiltrating lymphocytes, they are better suited for therapeutic use due to their broader tumoricidal activity.
- the tumoricidal cells T produced according to the method of the invention are T -Cells
- Another distinguishing criterion between NK cells and tumoricidal T cells is that NK cells recognize the tumor cell line K-562 and destroy it cytotoxically, whereas tumoricidal T cells only inhibit the cell line K-562 for a limited time during growth
- a time-limited inhibition in the sense of the invention is to be understood that the cells of the cell culture are not killed, but only inhibited in their proliferation, preferably completely inhibited in their proliferation. The inhibition of proliferation is reversible and can be reversed by separating the tumoricidal T cells and the cells of the cell line K-562.
- a tumoricidal effect is not only to be understood as the killing (in particular lysis) of the tumor cell lines examined, but also an anti-proliferation effect.
- This tumoricidal effect can e.g. are recognized by the cytotoxicity tests familiar to the person skilled in the art, e.g. the fact that the tumor cell lines, which are morphologically distinguishable from the tumor t-lymphocytes, disappear from the culture or at least remain in growth after prolonged cultivation with the tumor t-lymphocytes.
- the tumoricidal T lymphocytes are preferably CD3 + and / or CD4 +.
- Lymphocytes in the sense of the invention, are to be understood as preparations of white blood cells which can be obtained from whole blood, for example. Such methods are known to the person skilled in the art. For example, after a gradient centrifugation (Ficoll gradient), the fraction of mononuclear cells (PBMNC) containing the blood lymphocytes can be obtained.
- PBMNCs obtained in this way have to be pretreated so that specifically tumoricidal T lymphocytes are formed.
- the cells are pretreated using a lysosomotrophic substance, such as L-leucyl-leucine methyl ester or an analogous ester. Such substances are for example from PL.
- the lysosomotrophic pretreatment maintains the fraction of surviving lymphocytes in which the progenitor cells are enriched with tumoricidal T-lymphocytes.
- An anti-CD43 antibody is an antibody against the cell surface molecule CD43 (DeSmet, W. et al., In: Schlossman, SF, et al. [Eds.] Leukocyte Typing V, pp. 1706-1707, Oxford, United Kingdom: Oxford University Press, 1995).
- CD43 is a sialoglycoprotein that is formed on cells of the hematopoietic system and - with the exception of dendritic cells and a subpopulation of B lymphocytes - is expressed on all cells of the immune system (Fukuda, M., Glycobiology 1 [1991], 347-356 ).
- Such an antibody is preferably directed against the part of the CD43 molecule which is involved in the binding of CD43 to MHC class I molecules.
- the antibody can be monoclonal or polyclonal and by immunization, synthesis or recombinant methods be made. Complete antibodies or antibody derivatives which mediate a characteristic binding can be used. However, an antibody or antibody derivative is preferably used which is capable of crosslinking CD43 molecules on cell surfaces in an analogous manner to an intact CD43 antibody.
- one or more anti-CD2 antibodies are added to improve the yield of tumoricidal T lymphocytes, preferably a T cell stimulating pair (directed against two different epitopes of CD2) of anti-CD2 antibodies ( Schwarz, M., et al., J. Immunol. 154 (1995), 5813-5820; Moingeon, P., et al., Immunol. Rev. 111 (1989), 111-140).
- the lymphocytes are cultured with the anti-CD43 antibody expediently in conventional culture media over several days (preferably 5-30 days).
- the culture medium is preferably serum-free.
- An autologous serum is very particularly preferably used for the cultivation if autologous tumoricidal T-lymphocytes are to be prepared.
- the tumor tidal lymphocytes obtained in this way can, if necessary after cleaning, be administered to the patient as a therapeutic agent.
- tumoral T-lymphocytes with a wide tumor activity can be obtained without HLA restriction.
- a tumoricidal activity is understood to mean both a killing, in particular apoptosis-inducing and / or lysing, effect on the corresponding tumor cells and also a proliferation-inhibiting effect on these tumor cells.
- Blood lymphocytes are preferably used as lymphocytes. However, it is also possible to use tumor infiltrating lymphocytes (TLL) as well as lymphocytes from spleen or lymph nodes. It is preferred to clean the lymphocyte preparation before use. When using blood lymphocytes, it is advisable to deplete the erythrocytes.
- the fraction of the progenitor cells from tumoricidal T lymphocytes is enriched with the anti-CD43 antibody before cultivation.
- monocytes, macrophages, NK cells, suppressor T cells and allogen-reactive, cytotoxic T cells and their precursor cells are eliminated lysosomotrophically, preferably according to Thiele and Lipsky (The Journal of Immunology, Vol. 136, No. 3 (1986) , Pp. 1038-1048), incubated with L-leucyl-L-leucine methyl ester.
- lymphocytes preferably from the blood or from tumors of a donor.
- lymphocytes according to known methods, e.g. isolated using a Ficoll density gradient centrifugation.
- the lymphocytes left over after lysosomotrophic treatment are then cultured in a customary lymphocyte culture medium together with an anti-CD43 antibody.
- the antibody concentration is between 1 ng / ml - 100 ⁇ g / ml, preferably 10 ⁇ g / ml culture medium.
- Cultivation continues until the activation of tumoricidal T cells becomes apparent. This usually requires cultivation for around 8 days.
- the cultivation according to the invention enables activation of tumoricidal T lymphocytes without growth or differentiation factors, such as e.g. Lymphokines, especially interleukin-2, must be added. This is of particular advantage for the therapeutic use of the tumoral T lymphocytes obtained, since such factors can trigger side effects in the therapeutic application.
- human tumoricidal T-lymphocytes can be obtained without differentiation or growth factors, such as lymphokines, in particular interleukin-2, having to be added, which can lead to side effects during therapy.
- Another object of the invention is therefore the use of the method according to the invention for the production of a therapeutic agent which is used in tumor therapy.
- the tumoricidal T-lymphocytes produced according to the invention are washed according to methods familiar to the person skilled in the art (e.g. by centrifugation and resuspension of the pellet in physiological saline solution with repeated, e.g. triple repetition), if appropriate isolated and in a for suitable medium (e.g.
- lymphocytes can also be activated in vivo by application of an anti-CD43 antibody to form tumoricidal T lymphocytes.
- the antibody is taken up and applied in a medium suitable for the application, such as, for example, physiological saline.
- the tumoricidal T lymphocytes can also be used for the elimination of tumor cells in a cell preparation ex vivo. It can preferably be used to isolate tumor cells from stem cell isolates (eg bone marrow stem cells) by culturing with tumoricidal T lymphocytes (purging). The stem cells cleaned in this way can be re-implanted in the patient after radiation or chemotherapy (autologous bone marrow transplantation).
- stem cell isolates eg bone marrow stem cells
- the stem cells cleaned in this way can be re-implanted in the patient after radiation or chemotherapy (autologous bone marrow transplantation).
- Antibodies against the human CD43 molecule are described by DeSmet, W., et al. (In: Schlossman, S.F., et al. [Eds.] Leukocyte Typing V, pp. 1706-1707, Oxford, United Kingdom: Oxford University Press, 1995).
- the anti-CD43 antibody designated as "6F5" is suitable.
- an increase in the T-lymphocytes thus obtained is carried out.
- the propagation is preferably carried out according to the method described in the international application PCT / EP97 / 01924.
- the cell line HB 654 was deposited on March 24, 1993 with the German Collection for Cell Cultures and Microorganisms GmbH, Mascheroder Weg 1 b, D-38124 Braunschweig under the number DSM ACC 2122.
- the cell line HB 617 was deposited on March 1st, 1994 with the German Collection for Cell Cultures and Microorganisms GmbH, Mascheroder Weg 1 b, D-38124 Braunschweig under the number DSM ACC 2166.
- Mononuclear cells from the peripheral blood (PBMNC) of human donors are separated from the erythrocytes by gradient centrifugation (lymphocyte separation medium, Boehringer Manheim GmbH (BM)), washed twice with phosphate-buffered saline (Boehringer Mannheim GmbH (BM)) and at a density of approx 5 x 10 ⁇ cells / ml RPMI-1640 medium (Boehringer Mannheim GmbH (BM)) according to Thiele and Lipsky (The Journal of Immunology, Vol. 136, No. 3 (1986), pp. 1038-1048) at 250 ⁇ M leucyl-leucine methyl ester (Boehringer Mannheim GmbH (BM)) incubated for 20 minutes at room temperature.
- BM peripheral blood
- the surviving cells After washing twice with RPMI-1640 medium, the surviving cells at a density of approx. 2 x 10 ⁇ cells / ml in X-Vivo-20 medium (Bio-Whittacker), which the anti-CD43 antibody 6F5 in a Concentration of 10 ⁇ g / ml has been added, cultured at 37 ° C. in an 8% CO 2 atmosphere. On day 5 after the beginning of the culture, half of the medium is renewed and fresh anti-CD43 antibody 6F5 is added to a final concentration of 10 ⁇ g / ml. On day 10, after the culture has been set up, the cells are used for example 3.
- the phenotyping of the cells on day 10 of the culture shows that> 95% of the cells are CD3 +. Cells with the CD 14 or CD 16 markers are not found.
- lymphocytes are prepared from the blood of a human donor by gradient centrifugation and treatment with leucyl-leucine methyl ester.
- the lymphocytes are suspended in Isove's modified DMEM (Gibco), to which 10% heat-inactivated (56 ° C / 30 minutes), autologous serum has been added, at a density of 1 x 10 ⁇ cells / ml and the anti-CD43 antibody 6F5 and the anti-CD2 antibodies TS2 / 18 and VIT13 (Schwarz, M., et al., J. Immunol. 154 (1995), 5813-5820) were added in a concentration of 10 ⁇ g / ml each. On day 5, half of the culture medium with the antibodies contained in it is renewed. The cell count on day 10 after the start of the culture showed that the lymphocytes had increased 2.2-fold.
- the tumoricidal T-lymphocytes obtained according to Example 1 are added to cultures of human tumor lines (see Tables I and II). The tumoricidal effect on these tumor cells is monitored under the microscope. These different tumor cell lines are killed or their growth is inhibited with the tumoricidal T-lymphocytes according to the invention.
- microorganism referred to under I has been received by this International Depository on (date of deletion) and an application has been made to convert this deletion into a deposit according to
- microorganism referred to under I has been received by this International Depositary on (date of the deposit) and an application to convert this deposit into a deposit under the Budapest Treaty has been received on (date of receipt of the application for conversion).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002270117A CA2270117A1 (en) | 1996-10-30 | 1997-10-29 | Process for producing tumoricide t-lymphocytes |
EP97948827A EP0942961A1 (de) | 1996-10-30 | 1997-10-29 | Verfahren zur herstellung von tumoriziden t-lymphozyten |
AU69088/98A AU6908898A (en) | 1996-10-30 | 1997-10-29 | Process for producing tumoricide T-lymphocytes |
JP10520046A JP2000504230A (ja) | 1996-10-30 | 1997-10-29 | 殺腫瘍性tリンパ球の製造法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96117376.2 | 1996-10-30 | ||
EP96117376 | 1996-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998018907A1 true WO1998018907A1 (de) | 1998-05-07 |
Family
ID=8223342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/005957 WO1998018907A1 (de) | 1996-10-30 | 1997-10-29 | Verfahren zur herstellung von tumoriziden t-lymphozyten |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0942961A1 (de) |
JP (1) | JP2000504230A (de) |
AU (1) | AU6908898A (de) |
CA (1) | CA2270117A1 (de) |
WO (1) | WO1998018907A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001063511A1 (en) * | 2000-02-24 | 2001-08-30 | Gyu Ho Kim | Prepayment and profit distribution system for unrealized goods on internet |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4596916B2 (ja) * | 2002-09-05 | 2010-12-15 | メディミューン,エルエルシー | Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0440373A1 (de) * | 1990-01-25 | 1991-08-07 | Bristol-Myers Squibb Company | Verfahren zur Aktivierung der zytolytischen Wirkung von Lymfozyten unter Verwendung von anti-CD28-Antikörper |
WO1994023014A1 (de) * | 1993-03-31 | 1994-10-13 | Boehringer Mannheim Gmbh | Tumorizide t-lymphozyten |
WO1996015227A1 (en) * | 1994-11-14 | 1996-05-23 | Novartis Ag | Methods of inducing cell death of primitive hematopoietic cells and compositions for induction thereof |
-
1997
- 1997-10-29 JP JP10520046A patent/JP2000504230A/ja active Pending
- 1997-10-29 CA CA002270117A patent/CA2270117A1/en not_active Abandoned
- 1997-10-29 EP EP97948827A patent/EP0942961A1/de not_active Withdrawn
- 1997-10-29 WO PCT/EP1997/005957 patent/WO1998018907A1/de not_active Application Discontinuation
- 1997-10-29 AU AU69088/98A patent/AU6908898A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0440373A1 (de) * | 1990-01-25 | 1991-08-07 | Bristol-Myers Squibb Company | Verfahren zur Aktivierung der zytolytischen Wirkung von Lymfozyten unter Verwendung von anti-CD28-Antikörper |
WO1994023014A1 (de) * | 1993-03-31 | 1994-10-13 | Boehringer Mannheim Gmbh | Tumorizide t-lymphozyten |
WO1996015227A1 (en) * | 1994-11-14 | 1996-05-23 | Novartis Ag | Methods of inducing cell death of primitive hematopoietic cells and compositions for induction thereof |
Non-Patent Citations (4)
Title |
---|
BEYERS, A.D. ET AL: "Activation of T lymphocytes via monoclonal antibodies against rat cell surface antigens with particular reference to CD2 antigen", IMMUNOLOGICAL REVIEWS, vol. 111, 1989, pages 59 - 77, XP000647939 * |
MENTZER S.J. ET AL: "Sialophorin, a surface sialoglycoprotein defective in the wiskott-aldrich syndrome, is involved in human T lymphocyte proliferation", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 165, 1987, pages 1383 - 1392, XP000670176 * |
VARGAS-CORTES M. ET AL: "Enhancement of human spontaneous cell-mediated cytotoxicity by a monoclonal antibody against the large sialoglycoprotein (CD43) on peripheral blood lymphocytes", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 27, 1988, pages 661 - 671, XP000670028 * |
WEBB M. ET AL: "Inhibition of mixed lymphocyte response by monoclonal antibody specific for a rat lymphocyte subset", NATURE, vol. 282, 1979, LONDON GB, pages 841 - 843, XP002029285 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001063511A1 (en) * | 2000-02-24 | 2001-08-30 | Gyu Ho Kim | Prepayment and profit distribution system for unrealized goods on internet |
Also Published As
Publication number | Publication date |
---|---|
CA2270117A1 (en) | 1998-05-07 |
AU6908898A (en) | 1998-05-22 |
EP0942961A1 (de) | 1999-09-22 |
JP2000504230A (ja) | 2000-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60026561T2 (de) | Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen | |
DE102017127984B4 (de) | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen | |
DE69834257T2 (de) | Natürliche killerzelllinien und verfahren zu ihrer verwendung | |
DE60218302T2 (de) | Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten | |
DE69910362T2 (de) | Anwendung der mesenchymalen stammzellen als immunsuppressiva | |
EP0885614B1 (de) | Verfahren zur ex vivo-Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper | |
DE69729455T2 (de) | Methode und zusammensetzungen zum erlangen reifer dendritischer zellen | |
US8603815B2 (en) | CD4+ CD25− T cells and Tr1-like regulatory T cells | |
EP0693120B1 (de) | Tumorizide t-lymphozyten | |
EP1331944B1 (de) | Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen | |
Werner et al. | DX5+ NKT cells display phenotypical and functional differences between spleen and liver as well as NK1. 1-Balb/c and NK1. 1+ C57Bl/6 mice | |
DE60117167T2 (de) | Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen | |
EP0911388A2 (de) | Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität | |
DE69815840T2 (de) | Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren | |
DE60130634T2 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
EP1381387B1 (de) | Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen | |
WO1998018907A1 (de) | Verfahren zur herstellung von tumoriziden t-lymphozyten | |
DE60016567T2 (de) | Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode | |
DE60038119T2 (de) | Dendritische zellen, aktiviert in anwesenheit von glucocorticoiden hormonen, sind in der lage, die antigenspezifische t-zell-antwort zu unterdrücken | |
DE60033955T2 (de) | Melanoma-impfstoff und seine herstellung und verwendung | |
DE60130206T2 (de) | Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen | |
EP2025747A1 (de) | Verfahren zur in-vitro-Amplifikation von regulatorischen T-Zellen | |
EP0910624B1 (de) | Verfahren zur herstellung und vermehrung von lymphozyten | |
DE69916302T2 (de) | Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen | |
AU756716B2 (en) | Development of regulatory cells as a means for treating autoimmune disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2270117 Country of ref document: CA Ref country code: CA Ref document number: 2270117 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997948827 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09297246 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997948827 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997948827 Country of ref document: EP |